Chain reaction of amyloid fibril formation with induction of basement membrane in familial amyloidotic polyneuropathy

Journal of Pathology

Volumn 219, Issue 4, 2009, Pages 481-490

  Misumi, Yohei ^a   Ando, Yukio ^a   Ueda, Mitsuharu ^a   Obayashi, Konen ^a   Jono, Hirofumi ^a   Su, Yu ^a   Yamashita, Taro ^a   Uchino, Makoto ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Amyloidosis; Basement membrane; Cardiomyocytes; Collagen IV; Electron microscopy; Familial amyloidotic polyneuropathy; Immunohistochemistry; Transthyretin; Vascular smooth muscle cells

Indexed keywords

AMYLOID; COLLAGEN TYPE 4; FIBRONECTIN; LAMININ;

ADULT; AGED; ARTICLE; AUTOPSY; BASEMENT MEMBRANE; BIOACCUMULATION; CELL ULTRASTRUCTURE; CONTROLLED STUDY; ELECTRON MICROSCOPY; FAMILIAL AMYLOID POLYNEUROPATHY; FEMALE; HEART MUSCLE; HEART MUSCLE CELL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MICROENVIRONMENT; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

ADULT; AGED; AMYLOID; AMYLOID NEUROPATHIES, FAMILIAL; BASEMENT MEMBRANE; CELL LINE; CELLS, CULTURED; COLLAGEN TYPE IV; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MEMBRANE PROTEINS; MICROSCOPY, ELECTRON; MIDDLE AGED; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, CARDIAC;

EID: 72249106474     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2618     Document Type: Article

References (48)

1. Ando Y, Nakamura M, Araki S. Transthyretin-related familial amyloidotic polyneuropathy. Arch Neurol 2005;62:1057-1062.
2. Coimbra A, Andrade C. Familial amyloid polyneuropathy: an electron microscope study of the peripheral nerve in five cases. I. Interstitial changes. Brain 1971;94:199-206.
3. Takahashi K, Yi S, Kimura Y, Araki S. Familial amyloidotic polyneuropathy type 1 in Kumamoto, Japan: a clinicopathologic, histochemical, immunohistochemical, and ultrastructural study. Hum Pathol 1991;22:519-527.
4. Sousa MM, Saraiva MJ. Neurodegeneration in familial amyloid polyneuropathy: from pathology to molecular signaling. Prog Neurobiol 2003;71:385-400.
5. Benson MD, Kincaid JC. The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve 2007;36:411-423. (Pubitemid 47512065)
6. Westermark P, Benson MD, Buxbaum JN. Amyloid fibril protein nomenclature - 2002. Amyloid 2002;99:197-200. (Pubitemid 35205211)
7. Connors LH, Lim A, Prokaeva T, Roskens VA, Costello CE. Tabulation of human transthyretin (TTR) variants, 2003. Amyloid 2003;10:160-184. (Pubitemid 37372400)
8. Yang M, Lei M, Bruschweiler R, Huo S. Initial conformational changes of human transthyretin under partially denaturing conditions. Biophys J 2005;89:433-443. (Pubitemid 41098298)
9. Lai Z, Colon W, Kelly JW. The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid. Biochemistry 1996;35:6470-6482. (Pubitemid 26164080)
10. Hammarström P, Jiang X, Hurshman AR, Powers ET, Kelly JW. Sequence-dependent denaturation energetics: a major determinant in amyloid disease diversity. Proc Natl Acad Sci U S A 2002;99:16427-16432. (Pubitemid 35470989)
11. Alexandrescu AT. Amyloid accomplices and enforcers. Protein Sci 2005;14:1-12.
12. Bellotti V, Merlini G. Current concepts on the pathogenesis of systemic amyloidosis. Nephrol Dial Transplant 1996;11:53-62. (Pubitemid 27076020)
13. Prelli F, Pras M, Frangione B. The primary structure of human tissue amyloid P component from a patient with primary idiopathic amyloidosis. J Biol Chem 1985;260:12895-12898. (Pubitemid 16209747)
14. Kisilevsky R. Heparan sulfate proteoglycans in amyloidogenesis: an epiphenomenon, a unique factor, or the tip of a more fundamental process? Lab Invest 1990;63:589-591.
15. Ancsin JB. Amyloidogenesis: historical and modern observations point to heparan sulfate proteoglycans as a major culprit. Amyloid 2003;10:67-79.
16. Hirschfield GM, Hawkins PN. Amyloidosis: new strategies for treatment. Int J Biochem Cell Biol 2003;35:1608-1613.
17. Pepys MB. A molecular correlate of clinicopathology in transthyretin amyloidosis. J Pathol 2009;217:1-3.
18. Puchtler H, Sweat F, Levine M. On the binding of Congo red by amyloid. J Histochem Cytochem 1962;10:355-364.
19. Bolmont T, Clavaguera F, Meyer-Luehmann M, Herzig MC, Radde R, Staufenbiel M, et al. Induction of tau pathology by intracerebral infusion of amyloid-β-containing brain extract and by amyloid-β deposition in APP x Tau transgenic mice. Am J Pathol 2007;171:2012-2020.
20. Sanders JE, Goldstein BS. Collagen fibril diameters increase and fibril densities decrease in skin subjected to repetitive compressive and shear stresses. J Biomech 2001;34:1581-1587.
21. Ando Y, Yamashita T, Nakamura M, Tanaka Y, Hashimoto M, Tashima K, et al. Down regulation of a harmful variant protein by replacement of its normal protein. Biochim Biophys Acta 1997;1362:39-46. (Pubitemid 28027110)
22. Obata K, Iwata K, Ichida T, Inoue K, Matsumoto E, Muragaki Y, et al. One step sandwich enzyme immunoassay for human type IV collagen using monoclonal antibodies. Clin Chim Acta 1989;181:293-303. (Pubitemid 19147937)
23. Yazaki M, Liepnieks JJ, Kincaid JC, Benson MD. Contribution of wild-type transthyretin to hereditary peripheral nerve amyloid. Muscle Nerve 2003;28:438-442. (Pubitemid 37193771)
24. Jiang X, Smith CS, Petrassi HM, Hammarström P, White JT, Sacchettini JC, et al. An engineered transthyretin monomer that is nonamyloidogenic, unless it is partially denatured. Biochemistry 2001;40:11442-11452. (Pubitemid 32911287)
25. Lashuel HA, Lai Z, Kelly JW. Characterization of the transthyretin acid denaturation pathways by analytical ultracentrifugation: implications for wild-type, V30M, and L55P amyloid fibril formation. Biochemistry 1998;37:17851-17864. (Pubitemid 29023940)
26. Sousa MM, Cardoso I, Fernandes R, Guimarães A, Saraiva MJ. Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates. Am J Pathol 2001;159:1993-2000. (Pubitemid 33104254)
27. Yamaguchi H, Yamazaki T, Lemere CA, Frosch MP, Selkoe DJ. Beta amyloid is focally deposited within the outer basement membrane in the amyloid angiopathy of Alzheimer's disease. An immunoelectron microscopic study. Am J Pathol 1992;141:249-259.
28. Sawabe M, Hamamatsu A, Ito T, Arai T, Ishikawa K, Chida K, et al. Early pathogenesis of cardiac amyloid deposition in senile systemic amyloidosis: close relationship between amyloid deposits and the basement membranes of myocardial cells. Virchows Arch 2003;442:252-257. (Pubitemid 36399219)
29. Wisniewski HM, Wegiel J. Beta-amyloid formation by myocytes of leptomeningeal vessels. Acta Neuropathol 1994;87:233-241. (Pubitemid 2074081)
30. Flanders KC, Lippa CF, Smith TW, Pollen DA, Sporn MB. Altered expression of transforming growth factor-beta in Alzheimer's disease. Neurology 1995;45:1561-1569.
31. Aumailley M, Gayraud B. Structure and biological activity of the extracellular matrix. J Mol Med 1998;76:253-265. (Pubitemid 28098711)
32. Donahue S, Zeman W, Watanabe I. Alterations of basement membranes of cerebral capillaries. J Neuropathol Exp Neurol 1967;26:397-411.
33. Laurie GW, Leblond CP, Martin GR. Localization of type IV collagen, laminin, heparan sulfate proteoglycan, and fibronectin to the basal lamina of basement membranes. J Cell Biol 1982;95:340-344.
34. Lyon AW, Narindrasorasak S, Young ID, Anastassiades T, Couchman JR, McCarthy KJ, et al. Co-deposition of basement membrane components during the induction of murine splenic AA amyloid. Lab Invest 1991;64:785-790.
35. 2-microglobulin amyloidosis - a comparative study with systemic AA and AL amyloidosis. Virchows Arch 1997;430:479-487.
36. Perlmutter LS, Chui HC. The beta-amyloid peptide of Alzheimer's disease decreases adhesion of vascular smooth muscle cells to the basement membrane. Brain Res Bull 1990;24:677-686.
37. Zahedi K. Characterization of the binding of serum amyloid P to laminin. J Biol Chem 1997;272:2143-2148. (Pubitemid 27058492)
38. Narindrasorasak S, Lowery D, Gonzalez-DeWhitt P, Poorman RA, Greenberg B, Kisilevsky R. High affinity interactions between the Alzheimer's β-amyloid precursor proteins and the basement membrane form of heparan sulfate proteoglycan. J Biol Chem 1991;266:12878-12883. (Pubitemid 21907281)
39. Ancsin JB, Kisilevsky R. Characterization of high affinity binding between laminin and the acute-phase protein, serum amyloid A. J Biol Chem 1997;272:406-413. (Pubitemid 27021173)
40. Zahedi K. Characterization of the binding of serum amyloid P to type IV collagen. J Biol Chem 1996;271:14897-14902. (Pubitemid 26194972)
41. Narindrasorasak S, Altman RA, Gonzalez-DeWhitt P, Greenberg BD, Kisilevsky R. An interaction between basement membrane and Alzheimer amyloid precursor proteins suggests a role in the pathogenesis of Alzheimer's disease. Lab Invest 1995;72:272-282.
42. Gressner OA, Weiskirchen R, Gressner AM. Biomarkers of liver fibrosis: clinical translation of molecular pathogenesis or based on liver-dependent malfunction tests. Clin Chim Acta 2007;381:107-113. (Pubitemid 46719142)
43. Matsumoto E, Matsumoto G, Ooshima A, Kikuoka H, Bessho H, Miyamura K, et al. Serum type IV collagen concentrations in diabetic patients with microangiopathy as determined by enzyme immunoassay with monoclonal antibodies. Diabetes 1990;39:885-890. (Pubitemid 20233719)
44. Kasuga I, Yonemaru M, Kiyokawa H, Ichinose Y, Toyama K. Clinical evaluation of serum type IV collagen 7S in idiopathic pulmonary fibrosis. Respirology 1996;1:277-281. (Pubitemid 126734129)
45. Sato Y, Kataoka K, Matsumori A, Sasayama S, Yamada T, Ito H, et al. Measuring serum amino terminal type III procollagen peptide, 7S domain of type IV collagen, and cardiac troponin T in patients with idiopathic dilated cardiomyopathy and secondary cardiomyopathy. Heart 1997;78:505-508. (Pubitemid 27515114)
46. Yazaki M, Mitsuhashi S, Tokuda T, Kametani F, Takei YI, Koyama J, et al. Progressive wild-type transthyretin deposition after liver transplantation preferentially occurs onto myocardium in FAP patients. Am J Transplant 2007;7:235-242. (Pubitemid 44952878)
47. Stangou AJ, Hawkins PN, Heaton ND, Rela M, Monaghan M, Nihoyannopoulos P, et al. Progressive cardiac amyloidosis following liver transplantation for familial amyloid polyneuropathy: implications for amyloid fibrillogenesis. Transplantation 1998;66:229-233. (Pubitemid 28370006)
48. Okamoto S, Yamashita T, Ando Y, Ueda M, Misumi Y, Obayashi K, et al. Evaluation of myocardial changes in familial amyloid polyneuropathy after liver transplantation. Intern Med 2008;47:2133-2137. (Pubitemid 351748613)